Autolus Limited
Nasdaq AUTL · London, United Kingdom
Works in Cardiovascular · Dermatology · Hematology · Immunology · Infectious disease · Neurology · Oncology · Renal & urogenital · Women's health
Autolus Limited is a clinical trial sponsor based in London, United Kingdom, listed as Nasdaq AUTL. It has 6 active clinical trials with 758 planned participants, across 9 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq AUTL
Pipeline · 6 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Autolus Limited
Autolus Limited is lead sponsor of 6 active clinical trials on ClinicalTrials.gov, with 758 planned participants, in Cardiovascular, Dermatology, Hematology, Immunology and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
Autolus Limited is based in London, United Kingdom and is listed as Nasdaq AUTL. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Autolus Limited; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Autolus Limited.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.